AlgiPharma Presenting at the Lipid Nanoparticle Development Europe Summit

We are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam.

With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will present on aspects of Lipid Nanoparticle Drug Delivery for Chronic Lung Diseases, and highlight some of the latest findings with AlgiPharma’s technology.

Join us in Amsterdam in October (see program here: https://ter.li/6fxvbr) or follow up with us directly to explore commercial opportunities.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

Delivery platforms for nanoparticles, small and large molecule based drugs.

Drug conjugates, adding functionality and reducing toxicity of parent compound.

API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma announces the appointment of Dr. Preston W. Campbell MD to the Board

We are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market.

 

Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he focused on Cystic Fibrosis (CF) drug discovery and development. After a successful career as a Pediatric Pulmonologist at Vanderbilt University, he joined the Foundation as Executive Vice President of Medical Affairs in 1998. In 2015, he became the Foundation’s President and CEO. During his tenure at the Foundation, he oversaw the Foundation’s research initiatives and its collaborative drug discovery and development program. He has extensive experience with numerous companies helping them navigate discovery or clinical development efforts. These resulted in the approval of twelve CF therapies including four that treat the basic defect in CF. The most recent was Trikafta, which benefits 93 percent of people with the disease. The survival of people with CF during this time has increased dramatically. He retired in 2023 and remains involved with drug discovery and development as an independent consultant. He is a citizen of the United States of America.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma presented at Lipid Nanoparticle Summit in Boston

AlgiPharma attended the LNP Formulation & Process Development conference in Boston, MA (17-19th April). Chief Scientific Officer Dr. Philip Rye presented AlgiPharma’s novel alginate oligosaccharide technology for overcoming inhalation barriers for LNP delivered therapeutics. His presentation highlighted the benefits and challenges associated with the inhalation delivery route, and how AlgiPharma’s technology can mediate the effective translocation of LNP therapeutics across the mucosal barrier.

AlgiPharma’s alginate oligosaccharide technology combined with existing LNP formulations represent a novel way to safely circumvent mucosal barrier challenges and significantly increase efficiency of inhaled LNP therapeutics.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

 

AlgiPharma announces the appointment of Dr. Charles A Johnson and Mr. Mike Walters to the Board

We are extremely pleased to announce the appointment of two experienced and high-calibre pharmaceutical experts to the AlgiPharma Board as non-executive Board Members. Their combined expertise will be invaluable in bringing AlgiPharma’s alginate technology closer to market.

Dr Charles Johnson is an independent consultant with over 30 years’ experience in the biotechnology industry. He gained his degree in medicine at the University of Cape Town and specialised in Paediatrics and subsequently pulmonology with a particular interest in cystic fibrosis. He completed his Paediatric Pulmonary Fellowship at Washington University and continued to practice medicine for 18 years before moving to the pharmaceutical and biotechnology industry. He has held leadership positions APT Pharmaceuticals, Inspire, Vertex and Neurotech. While Vice President and Head of the Immunology and Tissue Repair clinical group at Genentech he had responsibility for the development and approvals of XOLAIR®, for asthma, LUCENTIS® for wet age-related macular degeneration and RITUXAN® for rheumatoid arthritis. He has published widely in the scientific literature in his field of expertise and presented clinical data at international medical conferences. He is a citizen of the United States of America.

Mr. Mike Walters brings almost 40 years of business experience in pharmaceuticals. He began his career at Johnson and Johnson, and during his 14-year tenure took on roles of increasing responsibility within sales and marketing management and led training and senior management development for two of its operating companies. He left Johnson and Johnson in 1996 to start his first company, an organization focused on building the commercial infrastructure for organizations with no experience in product introductions and lifecycle management in the US. Much of his career has focused on Cystic Fibrosis, where he founded Source CF (which was sold to Eurand Pharmaceuticals in 2007), MVW Nutritionals and CF Global Services. He has led each of these companies to bring to market many of the products that are standard of care today. Mr. Walters attended Vanderbilt University, where he earned a Bachelor of Arts in Biochemistry and Chemistry. He is a citizen of the United States.

 

About AlgiPharma AS:
AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.
AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).
AlgiPharma is a privately owned company registered and domiciled in Norway.
For additional information contact:
Yngvar P. Berg, CEO: yngvar.berg@algipharma.com
Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

 

AlgiPharma Welcomes a New Member to the Team

AlgiPharma welcomes Mr Ole Tobias Fevang to the AlgiPharma team as accounting manager in support of the Norwegian operations. He has a master’s degree in finance from BI Norwegian Business School. He has previously worked at Norwegian banks (DNB Bank AS and Sparebanken Øst), and more recently four years as an accountant at the international financial services accounting and auditing firm BDO AS.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 6 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com